immunotherapy with chemotherapy, and which patients are unlikely to receive clinical benefit from immunotherapy. To address these and other research questions critical to improving patient outcomes, innovative research strategies and high-quality sources of data
Search Results
Martin J. Edelman, Daniel P. Raymond, Dwight H. Owen, Michelle B. Leavy, Kari Chansky, Sriram Yennu, Felix G. Fernandez, Carolyn J. Presley, Tithi Biswas, Gwendolyn P. Quinn, Matthew B. Schabath, Seth Sheffler-Collins, Laura Chu, and Richard E. Gliklich
Eric J. Bow
economic outcomes of hematopoietic stem-cell transplantation . J Clin Oncol 2001 ; 19 : 2201 – 2205 . 12 Sonis ST Elting LS Keefe D . Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and
George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles, and the Genitourinary Radiation Oncologists of Canada (GUROC)
pretreatment risk stratification systems have been published to support decision-making, interphysician communication, clinical trial stratification/design, and outcome reporting in nonmetastatic prostate cancer. Five unique commonly used systems (not
Christopher Nevala-Plagemann, Siddharth Iyengar, Andrew D. Trunk, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna
over the past several decades. This decrease is likely attributable to improved detection of early-stage disease through increased use of appropriate cancer screening and improvements in cytotoxic and targeted therapy. Unfortunately, outcomes for
P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri
, 5 , 11 However, data describing healthcare utilization and end-of-life (EoL) outcomes in this population are lacking. In the present study, we sought to describe the healthcare utilization and EoL outcomes among patients treated with CAR T
Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang
initiation of treatment with anti–PD-1 agents. Other than these few cases, there has been little published literature describing the endoscopic and histologic features of ICI-related esophagitis, treatment response, or clinical outcomes. There is a gap in
Michelle Guan, Gillian Gresham, Arvind Shinde, Isaac Lapite, Jun Gong, Veronica R. Placencio-Hickok, Christopher B. Forrest, and Andrew E. Hendifar
goals to be adequately considered when treatment decisions are made. 5 Historically, priorities in oncology emphasized clinical outcomes and the evaluation of tumor response based on physician interpretation of parameters such as laboratory values, tumor
Thomas A. D'Amico
patients. 12 , 13 Despite these outcomes, the advantages of thoracoscopic lobectomy seem to be underused. From 1999 to 2006, only 20% of all lobectomies for NSCLC were performed thoracoscopically by the board-certified thoracic surgeons participating in
Jacqueline Jonklaas
between effective radiation dose and outcome of radioiodine therapy for thyroid cancer . N Engl J Med 1983 ; 309 : 937 – 941 . 16. Maxon HR III Englaro EE Thomas SR . Radioiodine-131 therapy for well-differentiated thyroid cancer
Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming
treatment with a non–EGFR-targeting regimen. We analyzed disease bulk as an independent predictor of clinical outcomes associated with anti-EGFR therapies to build on the impact of sidedness in the treatment-refractory setting. Using a single
